JMP Securities Issues Positive Forecast for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its price target increased by JMP Securities from $11.00 to $14.00 in a research report released on Tuesday,Benzinga reports. They currently have a market outperform rating on the stock.

Separately, B. Riley raised OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.38.

OptimizeRx Price Performance

Shares of NASDAQ OPRX opened at $11.01 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.13. The stock has a 50 day moving average of $8.35 and a two-hundred day moving average of $6.37. The stock has a market cap of $203.61 million, a P/E ratio of -8.28 and a beta of 1.28.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.19. The business had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. On average, research analysts forecast that OptimizeRx will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the acquisition, the director now directly owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. The trade was a 472.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Whetstone Capital Advisors LLC acquired a new position in OptimizeRx during the fourth quarter worth $6,563,000. Royce & Associates LP purchased a new stake in OptimizeRx during the fourth quarter worth $5,198,000. Blair William & Co. IL boosted its position in OptimizeRx by 4.9% during the first quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock worth $5,465,000 after purchasing an additional 29,648 shares in the last quarter. Kennedy Capital Management LLC boosted its position in OptimizeRx by 57.8% during the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock worth $2,887,000 after purchasing an additional 217,676 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in OptimizeRx by 9.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock worth $2,159,000 after purchasing an additional 39,740 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.